Article

Basic science

Presented by Carrie Rinker Schaffer, PhD, University of Chicago

Related Videos
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
1 expert in this video
Clinical Benefits of BPH Treatments
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
Margaret Knoedler, MD, on Ho:YAG vs thulium fiber laser for ureteroscopy
Related Content
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
May 1st 2025

Safety, efficacy of vibegron sustained in men with OAB treated for BPH

Benjamin P. Saylor
The investigators reported an overall incidence of AEs of 29.6%.
Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
April 30th 2025

Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

Amy M. Pearlman, MD Ryan Terlecki, MD
A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC
April 30th 2025

TAR-200 boasts impressive DFS rates in papillary disease-only NMIBC

Hannah Clarke
Data showed a disease-free survival rate of 85.3% at 6 months and 81.1% at 9 months.
Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025
April 29th 2025

Pearls & Perspectives: Advancing sexual health in urology, with Rachel Rubin, MD, at AUA 2025

Amy M. Pearlman, MD Rachel Rubin, MD
Rachel Rubin, MD, discusses advancements in sexual health education and guidelines at the AUA meeting.
Site Logo
April 29th 2025

Advancing Patient Care: Innovations in Bladder Cancer

Sponsored by Pfizer
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
April 29th 2025

Cxbladder Triage may help patients avoid unnecessary cystoscopies

Benjamin P. Saylor
The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.
© 2025 MJH Life Sciences

All rights reserved.